One-time billionaire and ex-promoter of Fortis Healthcare, Religare and Ranbaxy Laboratories, Shivinder Mohan Singh, has signaled a fresh return to the healthcare sector through a reflective and “open invitation” shared on LinkedIn. The post — in the form of an invitation rather than a formal job advertisement — comes as Singh navigates a difficult legal and financial phase, including filing for personal insolvency.
In the post, Singh writes that “creating a great business takes a prerequisite; a clear vision, an unwavering purpose, systemic values and the right kind of people with a good work ethic.”
He notes that he is preparing for “another shift in health care” with more experience and a “deeper commitment” shaped by what he describes as the humbling events of the past decade.
Singh says he’s looking for “one bright, young professional” to work closely with him—someone who thinks clearly under pressure, communicates sharply, is curious, resourceful and discreet, and can balance detail with direction.
He notes that the role will be “intense, unstructured and deeply rewarding” and will offer a round-the-clock perspective on building an organization from scratch and working with leading minds in the healthcare sector.
The invitation generated significant engagement on LinkedIn, with netizens welcoming his return and supporting the opportunity.
“Welcome back sir. All the best for the second shift…God bless you.”
“I played this exact role over a decade ago…those years were truly character building. I wholeheartedly recommend this position.”
“This is truly inspiring. I look forward to seeing you build impact from scratch again.”
“It would be our privilege to work with you.
Legal and financial background
Singh’s announcement comes even as he moved the National Company Law Tribunal (NCLT) seeking personal insolvency.
Earlier this week, he filed a Section 94 of the Insolvency and Bankruptcy Code (IBC) claim that his liabilities significantly exceed his current assets. The matter was briefly heard by a two-judge bench comprising Mahendra Khandelwal and Subrata Kumar Dash and posted for further hearing on 20 May.
According to the filing, Singh’s financial distress stems primarily from:
Entitlement to return exceeding ₹3,500 million dollars went to Japanese pharmaceutical major Daiichi Sankyo in arbitration.
Seizure and disposal of property in connection with ongoing execution proceedings.
Financial Mismanagement and Liabilities Associated with RHC Holding Pvt. s.r.o., where he worked as a corporate guarantor.
Singh said in his lawsuit that most of his assets were either seized or liquidated at greatly reduced value as a result of protracted litigation and enforcement actions.
